PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18404470-1 2006 Cytosolic 5" nucleotidase II (cN-II) catalyses both the hydrolysis of a number of nucleoside monophosphates (e.g., IMP + H2O--> inosine + Pi), and the phosphate transfer from a nucleoside monophosphate donor to the 5" position of a nucleoside acceptor (e.g., IMP + guanosine --> inosine + GMP). Nucleosides 82-92 5'-nucleotidase, cytosolic II Homo sapiens 0-28 18404470-1 2006 Cytosolic 5" nucleotidase II (cN-II) catalyses both the hydrolysis of a number of nucleoside monophosphates (e.g., IMP + H2O--> inosine + Pi), and the phosphate transfer from a nucleoside monophosphate donor to the 5" position of a nucleoside acceptor (e.g., IMP + guanosine --> inosine + GMP). Nucleosides 82-92 5'-nucleotidase, cytosolic II Homo sapiens 30-35 12907246-5 2003 We investigated the dephosphorylation of the 5"-phosphates of commonly used nucleoside analogs by two cytosolic (cN-II and dNT-1) and one mitochondrial (dNT-2) nucleotidase. Nucleosides 76-86 5'-nucleotidase, cytosolic II Homo sapiens 113-118 16629121-5 2006 Cytoplasmic 5"-nucleotidase cN-II can degrade this clinically useful cytotoxic nucleoside analogue and its overexpression is thus likely to be involved in resistance to this compound. Nucleosides 79-89 5'-nucleotidase, cytosolic II Homo sapiens 28-33 15946667-2 2005 In many vertebrate tissues, cytosolic 5"-nucleotidase II (cN-II) either hydrolyses or phosphorylates a number of purine (monophosphorylated) nucleosides through a scheme common to the Haloacid Dehalogenase superfamily members. Nucleosides 141-152 5'-nucleotidase, cytosolic II Homo sapiens 28-56 15946667-2 2005 In many vertebrate tissues, cytosolic 5"-nucleotidase II (cN-II) either hydrolyses or phosphorylates a number of purine (monophosphorylated) nucleosides through a scheme common to the Haloacid Dehalogenase superfamily members. Nucleosides 141-152 5'-nucleotidase, cytosolic II Homo sapiens 58-63 87197-0 1979 Inhibition of human lung cyclic GMP and cyclic AMP phosphodiesterases by certain nucleosides, nucleotides, and pharmacological phosphodiesterase inhibitors. Nucleosides 81-92 5'-nucleotidase, cytosolic II Homo sapiens 32-35 12916861-10 2003 The observation that cytosolic cN-II is able to phosphorylate purine nucleosides has initiated studies on its potential participation in the metabolism of anticancer agents and in the development of cN-II inhibitory substances. Nucleosides 69-80 5'-nucleotidase, cytosolic II Homo sapiens 31-36 32970317-1 2021 PURPOSE: Purine metabolism involves various intracellular and extracellular enzymes, including cN-II and CD73 that dephosphorylate intracellular and extracellular nucleoside monophosphates into their corresponding nucleosides. Nucleosides 214-225 5'-nucleotidase, cytosolic II Homo sapiens 95-100 25656700-3 2015 In this paper we present evidence showing that, among the commonly used cytotoxic nucleoside analogs, fludarabine can act as a cN-II inhibitor. Nucleosides 82-92 5'-nucleotidase, cytosolic II Homo sapiens 127-132 31778791-6 2020 Indeed, inhibition of cN-II with anthraquinone-2,6-disulfonic acid (AdiS) further potentiated the synergistic action of AC220 and cytarabine, at low concentrations of this nucleoside analog. Nucleosides 172-182 5'-nucleotidase, cytosolic II Homo sapiens 22-27 30798051-1 2019 The development of cytosolic 5"-nucleotidase II (cN-II) inhibitors is essential to validate cN-II as a potential target for the reversion of resistance to cytotoxic nucleoside analogues. Nucleosides 165-175 5'-nucleotidase, cytosolic II Homo sapiens 19-47 30798051-1 2019 The development of cytosolic 5"-nucleotidase II (cN-II) inhibitors is essential to validate cN-II as a potential target for the reversion of resistance to cytotoxic nucleoside analogues. Nucleosides 165-175 5'-nucleotidase, cytosolic II Homo sapiens 49-54 30798051-1 2019 The development of cytosolic 5"-nucleotidase II (cN-II) inhibitors is essential to validate cN-II as a potential target for the reversion of resistance to cytotoxic nucleoside analogues. Nucleosides 165-175 5'-nucleotidase, cytosolic II Homo sapiens 92-97 26462774-1 2015 OBJECTIVE: To investigate the expression level and analyze the clinical significance of NT5C2, which is an nucleoside analogues metabolism related gene, in children with acute leukemia (AL). Nucleosides 107-117 5'-nucleotidase, cytosolic II Homo sapiens 88-93 27906612-1 2016 The 5"-nucleotidase cN-II has been shown to be associated with the sensitivity to nucleoside analogues, the survival of cytarabine treated leukemia patients and to cell proliferation. Nucleosides 82-92 5'-nucleotidase, cytosolic II Homo sapiens 20-25 26079827-6 2015 Cells with decreased cN-II expression were resistant to the nucleoside analog fludarabine confirming the involvement of cN-II in the metabolism of this drug. Nucleosides 60-70 5'-nucleotidase, cytosolic II Homo sapiens 21-26 25998135-6 2015 On the other hand, expression of green fluorescent protein (GFP)-fused wild type or hyperactive mutant (R367Q) cN-II increased the activity and also decreased the sensitivity to nucleoside analogues. Nucleosides 178-188 5'-nucleotidase, cytosolic II Homo sapiens 111-116 23377281-3 2013 Using whole-exome sequencing, we identify mutations in the cytosolic 5"-nucleotidase II gene (NT5C2), which encodes a 5"-nucleotidase enzyme that is responsible for the inactivation of nucleoside-analog chemotherapy drugs, in 20/103 (19%) relapse T cell ALLs and 1/35 (3%) relapse B-precursor ALLs. Nucleosides 185-195 5'-nucleotidase, cytosolic II Homo sapiens 94-99 24607586-1 2014 The cytosolic 5"-nucleotidase II (cN-II) has been proposed as an attractive molecular target for the development of novel drugs circumventing resistance to cytotoxic nucleoside analogues currently used for treating leukemia and other malignant hemopathies. Nucleosides 166-176 5'-nucleotidase, cytosolic II Homo sapiens 4-32 24607586-1 2014 The cytosolic 5"-nucleotidase II (cN-II) has been proposed as an attractive molecular target for the development of novel drugs circumventing resistance to cytotoxic nucleoside analogues currently used for treating leukemia and other malignant hemopathies. Nucleosides 166-176 5'-nucleotidase, cytosolic II Homo sapiens 34-39 22174667-2 2011 Beside this physiological function, high level of cN-II expression is correlated with abnormal patient outcome when treated with cytotoxic nucleoside analogues. Nucleosides 139-149 5'-nucleotidase, cytosolic II Homo sapiens 50-55 23220537-1 2013 Clinical and preclinical observations have lead to the hypothesis that 5"-nucleotidase cN-II could constitute a therapeutic target in oncology, either per se or to increase the activity of cytotoxic nucleoside analogs. Nucleosides 199-209 5'-nucleotidase, cytosolic II Homo sapiens 87-92 23992314-1 2013 The cytoplasmic 5"-nucleotidase cN-II is involved in the regulation of endogenous pools of nucleosides and nucleotides together with nucleoside kinases and other intracellular enzymes. Nucleosides 91-102 5'-nucleotidase, cytosolic II Homo sapiens 32-37 21712425-12 2011 These results suggest that genetic variations in NT5C2 influence its expression and, potentially, cellular responses to nucleoside analogs. Nucleosides 120-130 5'-nucleotidase, cytosolic II Homo sapiens 49-54 21029378-2 2010 cN-II catalyses both the hydrolysis of nucleotides and transfer of their phosphate moiety to a nucleoside acceptor through formation of a covalent phospho-intermediate. Nucleosides 95-105 5'-nucleotidase, cytosolic II Homo sapiens 0-5 20205377-6 2010 On the basis of the salt dependence of the reaction and comparison with the corresponding nucleoside, the dianionic phosphate of 5"-GMP is one binding site for Ag(+), although this electrostatic interaction is not a dominant contribution to the overall heat change. Nucleosides 90-100 5'-nucleotidase, cytosolic II Homo sapiens 132-135